Fenwick represented Belharra Therapeutics on the deal. Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, announced its multi-year collaboration with...
Fenwick represented Belharra Therapeutics on the deal. Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, announced its multi-year collaboration with...